TABLE 2.

Clonal analysis of protease- and Gag-coding regions of virus from PRO3006 patient A through 68 weeks of therapy

Sample	Treatmenta	Plasma HIV-1 RNA (copies/ml)	No. of clones with indicated mutation/no. tested (%)b
			P453L	L449F	I50V	M46L	M46I
Day 1	APV-ZDV-3TC	29,896
Week 4	APV-ZDV-3TC	18,879
Week 8	APV-ZDV-3TC	1,030	NDc	ND	ND	ND	ND
Week 12	APV-ZDV-3TC	1,213
Week 16	APV-ZDV-3TC	644
Week 20	APV-ZDV-3TC	4,391	11/12 (92)	1/12 (8)	12/12 (100)
Week 24	APV-ZDV-3TC	22,250	12/12 (100)		11/12 (92)
Week 28	APV-DDI-D4T	16,556	12/12 (100)		12/12 (100)
Week 32	APV-DDI-D4T	4,828	12/12 (100)		12/12 (100)	11/12 (92)
Week 36	APV-DDI-D4T	3,580	12/12 (100)		12/12 (100)		1/12 (8)
Week 44	APV-IDV-DDI-D4T	3,704	6/12 (50)	6/12 (50)	12/12 (100)		9/12 (75)
Week 48	APV-IDV-DDI-D4T	752	ND	ND	ND	ND	ND
Week 52	APV-IDV-DDI-D4T	<400	ND	ND	ND	ND	ND
Week 56	APV-IDV-DDI-D4T	582	ND	ND	ND	ND	ND
Week 60	APV-IDV-DDI-D4T	<400	ND	ND	ND	ND	ND
Week 64	APV-IDV-DDI-D4T	2,630	ND	ND	ND	ND	ND
Week 68	APV-IDV-DDI-D4T	3,292		12/12 (100)	12/12 (100)		12/12 (100)

^aD4T, stavudine; DDI, dideoxyinosine.

^bOther deviations from the HIV-1 consensus B comparator were detected in all clones.

^cND, not determined.